학술논문

Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients
Document Type
article
Author
Schubert, Klaus OliverThalamuthu, AnbupalamAmare, Azmeraw TFrank, JosephStreit, FabianAdl, MazdaAkula, NirmalaAkiyama, KazufumiArdau, RaffaellaArias, BárbaraAubry, Jean-MichelBacklund, LenaBhattacharjee, Abesh KumarBellivier, FrankBenabarre, AntonioBengesser, SusanneBiernacka, Joanna MBirner, ArminMarie-Claire, CynthiaCearns, MicahCervantes, PabloChen, Hsi-ChungChillotti, CaterinaCichon, SvenClark, Scott RCruceanu, CristianaCzerski, Piotr MDalkner, NinaDayer, AlexandreDegenhardt, FranziskaDel Zompo, MariaDePaulo, J RaymondÉtain, BrunoFalkai, PeterForstner, Andreas JFrisen, LouiseFrye, Mark AFullerton, Janice MGard, SébastienGarnham, Julie SGoes, Fernando SGrigoroiu-Serbanescu, MariaGrof, PaulHashimoto, RyotaHauser, JoannaHeilbronner, UrsHerms, StefanHoffmann, PerHou, LipingHsu, Yi-HsiangJamain, StephaneJiménez, EstherKahn, Jean-PierreKassem, LaylaKuo, Po-HsiuKato, TadafumiKelsoe, JohnKittel-Schneider, SarahFerensztajn-Rochowiak, EwaKönig, BarbaraKusumi, IchiroLaje, GonzaloLandén, MikaelLavebratt, CatharinaLeboyer, MarionLeckband, Susan GMaj, MarioManchia, MirkoMartinsson, LinaMcCarthy, Michael JMcElroy, SusanColom, FrancescMitjans, MarinaMondimore, Francis MMonteleone, PalmieroNievergelt, Caroline MNöthen, Markus MNovák, TomasO’Donovan, ClaireOzaki, NorioÖsby, UrbanPapiol, SergiPfennig, AndreaPisanu, ClaudiaPotash, James BReif, AndreasReininghaus, EvaRouleau, Guy ARybakowski, Janusz KSchalling, MartinSchofield, Peter RSchweizer, Barbara WSeverino, GiovanniShekhtman, TatyanaShilling, Paul DShimoda, KatzutakaSimhandl, ChristianSlaney, Claire MSquassina, AlessioStamm, Thomas
Source
Translational Psychiatry. 11(1)
Subject
Biological Psychology
Pharmacology and Pharmaceutical Sciences
Biomedical and Clinical Sciences
Psychology
Serious Mental Illness
Mental Health
Brain Disorders
Schizophrenia
Bipolar Disorder
Aetiology
2.1 Biological and endogenous factors
Mental health
Good Health and Well Being
Depression
Depressive Disorder
Major
Genetic Predisposition to Disease
Humans
Lithium
Multifactorial Inheritance
Risk Factors
Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium
Clinical Sciences
Public Health and Health Services
Clinical sciences
Neurosciences
Biological psychology
Language
Abstract
Lithium is the gold standard therapy for Bipolar Disorder (BD) but its effectiveness differs widely between individuals. The molecular mechanisms underlying treatment response heterogeneity are not well understood, and personalized treatment in BD remains elusive. Genetic analyses of the lithium treatment response phenotype may generate novel molecular insights into lithium's therapeutic mechanisms and lead to testable hypotheses to improve BD management and outcomes. We used fixed effect meta-analysis techniques to develop meta-analytic polygenic risk scores (MET-PRS) from combinations of highly correlated psychiatric traits, namely schizophrenia (SCZ), major depression (MD) and bipolar disorder (BD). We compared the effects of cross-disorder MET-PRS and single genetic trait PRS on lithium response. For the PRS analyses, we included clinical data on lithium treatment response and genetic information for n = 2283 BD cases from the International Consortium on Lithium Genetics (ConLi+Gen; www.ConLiGen.org ). Higher SCZ and MD PRSs were associated with poorer lithium treatment response whereas BD-PRS had no association with treatment outcome. The combined MET2-PRS comprising of SCZ and MD variants (MET2-PRS) and a model using SCZ and MD-PRS sequentially improved response prediction, compared to single-disorder PRS or to a combined score using all three traits (MET3-PRS). Patients in the highest decile for MET2-PRS loading had 2.5 times higher odds of being classified as poor responders than patients with the lowest decile MET2-PRS scores. An exploratory functional pathway analysis of top MET2-PRS variants was conducted. Findings may inform the development of future testing strategies for personalized lithium prescribing in BD.